Lesley A. Stevenson

Aberdeen, SCT AB252ZD, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.

Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.

Journal: Journal of medicinal chemistry

Published: July 18, 2022

Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R).

Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R).

Journal: Frontiers in chemistry

Published: July 01, 2022

Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593.

Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593.

Journal: Frontiers in pharmacology

Published: April 13, 2022

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells.

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells.

Journal: Molecules (Basel, Switzerland)

Published: April 05, 2022

CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n‑butyl‑diphenylcarboxamides as allosteric modulators.

CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n‑butyl‑diphenylcarboxamides as allosteric modulators.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: September 18, 2021

Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor.

Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor.

Journal: European journal of medicinal chemistry

Published: September 01, 2020

PSNCBAM-1 analogs: Structural evolutions and allosteric properties at cannabinoid CB1 receptor.

PSNCBAM-1 analogs: Structural evolutions and allosteric properties at cannabinoid CB1 receptor.

Journal: European journal of medicinal chemistry

Published: April 15, 2020

Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.

Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.

Journal: Frontiers in molecular neuroscience

Published: July 01, 2019

Identification of the First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief.

Identification of the First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief.

Journal: Journal of medicinal chemistry

Published: July 11, 2018

Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats.

Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats.

Journal: British journal of pharmacology

Published: May 29, 2017

Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.

Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.

Journal: ACS chemical neuroscience

Published: January 20, 2017

Big conductance calcium-activated potassium channel openers control spasticity without sedation.

Big conductance calcium-activated potassium channel openers control spasticity without sedation.

Journal: British journal of pharmacology

Published: January 05, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026